Special Issue "Leukemia Arising from Chemical Exposures and Chemotherapeutic Drugs"
A special issue of International Journal of Environmental Research and Public Health (ISSN 1660-4601).
Deadline for manuscript submissions: closed (31 March 2012)
Dr. Luoping Zhang
Division of Environmental Health Sciences, School of Public Health, University of California at Berkeley, Berkeley, CA 94720, USA
Phone: +1 510 643 5189
Fax: +1 510 642 0427
Interests: the impact and mechanisms of exposures to toxic chemicals on human health, particularly in carcinogenesis and leukemogenesis; application of omic technologies in molecular epidemiological studies; and the development of new tools and assays to explore relevant biomakers
The etiology of the blood cancer leukemia is still largely unknown; however, exposures to toxic chemicals and cancer-therapeutic drugs can cause leukemia in adults and children. Benzene is a well established leukemogen and occupational exposure to formaldehyde has recently been shown to increase leukemia risk. Additionally, a portion of primary cancer patients develop acute myeloid leukemia (AML) after treatment with chemotherapeutic drugs, such as alkylating agents (melphalan etc) and DNA topoisomerase II (Topo II) inhibitors (etoposide etc.). Evidence suggests that the leukemia associated with exposure to different types of leukemogen exhibits specific molecular changes. For instance, therapy-related AML resulting from treatment with alkylating agents is mainly associated with loss of chromosomes 5 and 7, while Topo II inhibitor-induced AML is commonly associated with chromosomal translocations. Although chromosomal aneuploidy and rearrangements are hallmarks of leukemia, it is not well understood how these chemicals interact with normal hematopoietic stem/progenitor cells and disrupt bone marrow niches. This special issue will focus on molecular (genetic and epigenetic) mechanisms of chemically-induced leukmogenesis in exposed humans, experimental animal models and in vitro systems. We will accept original research reports, short communications/commentaries, and limited review papers deemed relevant.
Dr. Luoping Zhang
- Therapy-related leukemia
- Alkylating agents
- DNA topoisomerase II inhibitors